Withdrawn application: Dupixent, 24/06/2026

Human medicines European public assessment report (EPAR): Kigabeq, vigabatrin, Date of authorisation: 20/09/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Lumykras, sotorasib, Date of authorisation: 06/01/2022, Revision: 8, Status: Authorised

Lumykras : EPAR - Risk management plan

Human medicines European public assessment report (EPAR): Orkambi, lumacaftor,ivacaftor, Date of authorisation: 19/11/2015, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Cometriq, cabozantinib, Date of authorisation: 21/03/2014, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Ryjunea, atropine sulfate, Date of authorisation: 02/06/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Voriconazole Accord, voriconazole, Date of authorisation: 16/05/2013, Revision: 23, Status: Authorised

Academia